XBP-1 Drives Multiple Myeloma Development
Author Information
Author(s): D. R. Carrasco, K. Sukhdeo, M. Protopopova, R. Sinha, M. Enos, D. E. Carrasco, M. Zheng, M. Mani, J. Henderson, G. S. Pinkus, N. Munshi, J. Horner, E. V. Ivanova, A. Protopopov, K. C. Anderson, G. Tonon, R. A. DePinho
Primary Institution: Dana-Farber Cancer Institute and Harvard Medical School
Hypothesis
Enforced B cell lineage-directed transgene expression of factors driving plasma-cell differentiation will enhance the development of a MM-like disease.
Conclusion
The study demonstrates that XBP-1s overexpression alone can lead to a disease model that mirrors human multiple myeloma.
Supporting Evidence
- 60% of transgenic mice developed skin alterations resembling human conditions.
- 26% of transgenic mice progressed from MGUS to frank MM by 14-24 months.
- Elevated serum immunoglobulin levels were observed in transgenic mice.
Takeaway
Scientists created special mice that can develop a disease similar to multiple myeloma, helping them understand how this cancer starts and grows.
Methodology
Transgenic mice were engineered to express the XBP-1s isoform, and various analyses were performed to assess disease progression and gene expression.
Limitations
The model may not fully replicate all aspects of human multiple myeloma, particularly in terms of genetic instability.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website